Evidence map›Paper›PMID 39977387›Full record

ArticleThe Journal of urology2025

The Absolute Volume of Gleason Pattern 4 on Radical Prostatectomy Is More Strongly Associated With Advanced Stage and Biochemical Recurrence Than Gleason Grade Groups.

Simone Scuderi, Amy L Tin, Jared Klug, Shaun Porwal, Leonardo Quarta, Margherita Ciabattini, Nazario Pio Tenace, Riccardo Leni, Roberta Lucianò, Armando Stabile and 5 more

Abstract read
In one paragraph

Article in The Journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Simone ScuderiUnit of Urology, Division of Oncology, Gianfranco Soldera Prostate Cancer Lab|IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.ORCID 0000-0003-0071-1868
Amy L TinDepartment of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Jared KlugDepartment of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Shaun PorwalDepartment of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Leonardo QuartaUnit of Urology, Division of Oncology, Gianfranco Soldera Prostate Cancer Lab|IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Margherita CiabattiniUnit of Urology, Division of Oncology, Gianfranco Soldera Prostate Cancer Lab|IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Nazario Pio TenaceDepartment of Pathology, IRCCS Ospedale San Raffaele, Milan, Italy.
Riccardo LeniUnit of Urology, Division of Oncology, Gianfranco Soldera Prostate Cancer Lab|IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Roberta LucianòDepartment of Pathology, IRCCS Ospedale San Raffaele, Milan, Italy.
Armando StabileUnit of Urology, Division of Oncology, Gianfranco Soldera Prostate Cancer Lab|IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Giorgio GandagliaUnit of Urology, Division of Oncology, Gianfranco Soldera Prostate Cancer Lab|IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
James A EasthamDepartment of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Francesco MontorsiUnit of Urology, Division of Oncology, Gianfranco Soldera Prostate Cancer Lab|IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Alberto BrigantiUnit of Urology, Division of Oncology, Gianfranco Soldera Prostate Cancer Lab|IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Andrew J VickersDepartment of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
SPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI JAMES A EASTHAM · 2001 to 2026
$63.0M
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629
6 · The paper itself

Abstract

purposeInternational Society of Urological Pathology (ISUP) Grade Group (GG) is based on the relative proportion of Gleason patterns 3 and 4. We investigated whether absolute pattern 4 volume is more strongly associated with advanced stage and biochemical recurrence than GG in patients with pattern 4 but not 5. MATERIALS AND

methodsOverall, 1171 men received radical prostatectomy. Advanced stage definitions were extraprostatic extension (EPE) or seminal vesicle invasion (SVI) or lymph nodal invasion (LNI), and SVI or LNI. We explored the association between pattern 4 volume and percentage, and GG with advanced stage and recurrence using logistic and Cox regressions. We examined whether incorporating pattern 4 percentage improved the accuracy of a model including pattern 4 volume, PSA, and cT stage.

resultsOverall, 649, 381, and 141 patients had GG2, GG3, and GG4. EPE, SVI, and LNI were in 643, 84, and 57 men. For the EPE, SVI, or LNI outcome, pattern 4 volume showed higher discrimination (0.748) than ISUP (0.693) and pattern 4 percentage (0.724). Results were strengthened when outcome was SVI or LNI and excluded patients without nodal dissection. Pattern 4 volume showed higher discrimination for recurrence (0.705) than ISUP (0.675) or pattern 4 percentage (0.680). Pattern 3 volume did not increase discrimination when added to pattern 4. PSA levels were driven by pattern 4 volume, with pattern 3 and benign volumes having less impact.

conclusionsThe total amount of pattern 4 provides superior prognostic information to the relative proportion of patterns 3 and 4. Further research should investigate the best pattern 4 quantification method.

Indexed as

Neoplasm Recurrence, LocalProstatectomyProstatic NeoplasmsAgedHumansMaleMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasm StagingProstate-Specific AntigenRetrospective StudiesProstate-Specific AntigenGleason score pattern 4 percentageGleason score pattern 4 volumeprostate cancer

Identifiers

PMID39977387
PMCPMC12064379

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.